

Guidance has been Updated or Removed



U.S. Food and Drug Administration



Department of Health and Human Services

CENTER FOR DRUG EVALUATION AND RESEARCH

[FDA Home Page](#) | [CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)

[CDER Home](#) | [About CDER](#) | [Drug Information](#) | [Regulatory Guidance](#) | [CDER Calendar](#) | [Specific Audiences](#) | [CDER Archives](#)

Search GO powered by 

...This Guidance has been Removed

Biopharmaceutics

*Draft Guidance: Conjugated Estrogens, USP-LC-MS Method for Both Qualitative Chemical Characterization and Documentation of Qualitative Pharmaceutical Equivalence--**Withdrawn FR Notice***

[↑ Back to Top](#) [↖ Back to Guidance Page](#)

 PDF requires the free [Adobe Acrobat Reader](#)

Date created: September 15, 2006

[CDER Home Page](#) | [CDER Site Info](#) | [Contact CDER](#) | [What's New @ CDER](#)
[FDA Home Page](#) | [Search FDA Site](#) | [FDA A-Z Index](#) | [Contact FDA](#) | [Privacy](#) | [Accessibility](#) | [HHS Home Page](#)

FDA/Center for Drug Evaluation and Research